{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T16:09:22Z","timestamp":1775318962038,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.beha.2021.101306","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T14:37:06Z","timestamp":1630161426000},"page":"101306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical experience of CAR T cells for multiple myeloma"],"prefix":"10.1016","volume":"34","author":[{"given":"Gary L.","family":"Simmons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihisa","family":"Satta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda Puglianini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2021.101306_bib1","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.beha.2021.101306_bib2","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.beha.2021.101306_bib3","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2021.101306_bib4","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2021.101306_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/hematology.2020000110","article-title":"Bispecifics, trispecifics, and other novel immune treatments in myeloma","volume":"2020","author":"Lancman","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.beha.2021.101306_bib6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/hematology.2020000111","article-title":"Future of CAR T cells in multiple myeloma","volume":"2020","author":"Wudhikarn","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.beha.2021.101306_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/cancers12010015","article-title":"Therapeutic monoclonal antibodies and antibody products: current practices and development in multiple myeloma","volume":"12","author":"Bonello","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.beha.2021.101306_bib8","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2004-11-4463","article-title":"Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor","volume":"105","author":"Bellucci","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2021.101306_bib9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1182\/blood-2003-07-2559","article-title":"Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens","volume":"103","author":"Bellucci","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2021.101306_bib10","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.beha.2021.101306_bib11","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2021.101306_bib12","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti\u2013B-Cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: initial proof of concept results from a phase 1\/2 multicenter study (EVOLVE)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2021.101306_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2021.101306_bib15","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.beha.2021.101306_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.beha.2021.101306_bib17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"18","key":"10.1016\/j.beha.2021.101306_bib18","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2021.101306_bib19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2021.101306_bib20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-137156","article-title":"KarMMa-3: a phase 3 study of idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy vs standard regimens in relapsed and refractory multiple myeloma","volume":"136","author":"Delforge","year":"2020","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2021.101306_bib22","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-139009","article-title":"KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, in high-risk newly diagnosed multiple myeloma","volume":"136","author":"Usmani","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated results from the phase I CRB-402 study of anti-bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101306_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"19","key":"10.1016\/j.beha.2021.101306_bib26","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","article-title":"Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed\/refractory multiple","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE-1: a phase 1b\/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and\/or refractory multiple myeloma (R\/R MM)","volume":"134","author":"Madduri","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-136307","article-title":"CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed\/refractory multiple myeloma","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101306_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.beha.2021.101306_bib31","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/eji.1830230924","article-title":"Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-gamma or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine levels","volume":"23","author":"Matthys","year":"1993","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.beha.2021.101306_bib32","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3389\/fonc.2020.01243","article-title":"CAR T-cells in multiple myeloma: state of the art and future directions","volume":"10","author":"Rodr\u00edguez-Lobato","year":"2020","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.beha.2021.101306_bib33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.beha.2021.101306_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.beha.2021.101306_bib35","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"20","key":"10.1016\/j.beha.2021.101306_bib36","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.beha.2021.101306_bib37","doi-asserted-by":"crossref","first-page":"25764","DOI":"10.18632\/oncotarget.25359","article-title":"Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma","volume":"9","author":"Bu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.beha.2021.101306_bib38","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"20","key":"10.1016\/j.beha.2021.101306_bib39","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.beha.2021.101306_bib40","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.beha.2021.101306_bib41","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2021.101306_bib42","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.beha.2021.101306_bib43","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/cancers12040988","article-title":"Challenges for immunotherapy in multiple myeloma: bone marrow microenvironment-mediated immune suppression and immune resistance","volume":"12","author":"Holthof","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.beha.2021.101306_bib44","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood.V99.10.3838","article-title":"Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli","volume":"99","author":"Di Nicola","year":"2002","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-141062","article-title":"A fully-human armored BCMA CAR boosts function of CD4+ CAR-T cells and resists TGF-\u03b2 suppression in pre-clinical models of multiple myeloma","volume":"136","author":"Alabanza","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101306_bib46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"15_suppl","key":"10.1016\/j.beha.2021.101306_bib47","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2020.38.15_suppl.8002","article-title":"First-in-human data of ALLO-501 and ALLO-647 in relapsed\/refractory large B-cell or follicular lymphoma (R\/R LBCL\/FL): ALPHA study","volume":"38","author":"Neelapu","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.beha.2021.101306_bib48","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2021.101306_bib49","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clml.2020.04.007","article-title":"Allogeneic donor-derived anti-CD19 CAR T cell is a promising therapy for relapsed\/refractory B-all after allogeneic hematopoietic stem-cell transplantation","volume":"20","author":"Hua","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib50","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","article-title":"Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"132","author":"Benjamin","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-141477","article-title":"Preclinical evaluation of ALLO-605, an allogeneic BCMA turbocar TTM cell therapy for the treatment of multiple myeloma","volume":"136","author":"Sommer","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-139516","article-title":"Clinical development of a non-gene-edited allogeneic bcma-targeting CAR T-cell product in relapsed or refractory multiple myeloma","volume":"136","author":"Al-Homsi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101306_bib53","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.beha.2021.101306_bib54","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.beha.2021.101306_bib55","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41409-019-0601-6","article-title":"Adoptive cell therapy using engineered natural killer cells","volume":"54","author":"Rezvani","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib56","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-142813","article-title":"Generation of CAR-NK cells using a notch-mediated cell expansion and differentiation platform","volume":"136","author":"Chandrasekaran","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib57","first-page":"39","article-title":"Preclinical development of inducible MyD88\/CD40 (iMC)-Enhanced chimeric antigen receptor natural killer (GoCAR-NK) cells to target BCMA+ tumors","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101306_bib58","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-142750","article-title":"FT576: multi-specific off-the-shelf CAR-NK cell therapy engineered for enhanced persistence, avoidance of self-fratricide and optimized mab combination therapy to prevent antigenic escape and elicit a deep and durable response in multiple myeloma","volume":"136","author":"Goodridge","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2021.101306_bib59","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"355","key":"10.1016\/j.beha.2021.101306_bib60","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.beha.2021.101306_bib61","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.beha.2021.101306_bib62","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2008.07530.x","article-title":"CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden","volume":"144","author":"Feyler","year":"2009","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2021.101306_bib63","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2008-03-143222","article-title":"Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma","volume":"112","author":"Dhodapkar","year":"2008","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2021.101306_bib64","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.beha.2021.101306_bib65","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"issue":"22","key":"10.1016\/j.beha.2021.101306_bib66","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy","volume":"126","author":"Dhodapkar","year":"2015","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:52Z","timestamp":1761498412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692621000712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1521692621000712"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2021.101306","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical experience of CAR T cells for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2021.101306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101306"}}